

Press Release

June 3, 2024

Sumitomo Pharma Co., Ltd.

<u>Sumitomo Pharma Announces Organizational Realignment and Changes in the</u> <u>Positions Assumed by Executive Officer and Other Key Positions</u>

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) today announced the following organizational realignment and changes in the positions assumed by Executive Officer and other key positions.

I. Organizational Realignment (effective June 18, 2024) Corporate Department

Following the absorption-type company split of the Frontier Business to FrontAct Co., Ltd., Frontier Business Office is dissolved.

*The following press release has been issued in relation to this organizational realignment.

 Notice of Company Split (Simplified Absorption-type Company Split) of the Frontier Business and Notice of Business Acquisition by a Wholly-Owned Subsidiary of the Company (May 9, 2024)

https://www.sumitomo-pharma.com/news/assets/pdf/ene20240509.pdf

II. Change in the Positions Assumed by Executive Officer (effective June 18, 2024)

	,	· · · · · · · · · · · · · · · · · · ·
Position as of June 18, 2024	Current position	Name
Member, Board of Directors, Managing Executive Officer Global Data Design Office; Legal Affairs; Intellectual Property; IT Management & Digital Transformation	Member, Board of Directors, Managing Executive Officer Global Data Design Office; Legal Affairs; Intellectual Property; IT Management & Digital Transformation; Frontier Business Office	Hiroyuki Baba

^{*}Hiroyuki Baba will depart from Member of the Board of Directors upon the conclusion of the general shareholders' meeting scheduled to be held on June 25, 2024. The following press release has been issued in relation to departing Member of the Board of Directors.

 Sumitomo Pharma Appoints Toru Kimura as President and CEO and Changes in Board of Directors Including Representative Directors, Executive Officer, and the Positions Assumed by Executive Officers (May 14, 2024)

https://www.sumitomo-pharma.com/news/assets/pdf/ene20240514.4.pdf

III. Changes in Personnel

(1) Effective June 18, 2024

Corporate Department

Position as of June 18, 2024	Current position	Name
Representative Director, President and CEO, FrontAct Co., Ltd.	Vice President, Head of Frontier Business Office	Takehiko Nomura

(2) Effective June 25, 2024

Corporate Department

Position as of June 25, 2024	Current position	Name
Regenerative & Cellular Medicine		
Office;		
Regenerative & Cellular Medicine		
Kobe Center;	Vice President, Head of Regenerative	Tomokazu
Regenerative & Cellular Medicine	& Cellular Medicine Office	Nagano
Manufacturing Plant		
Vice President, Head of Regenerative		
& Cellular Medicine Office		

Contact:

Corporate Communications

Sumitomo Pharma Co., Ltd.

E-mail: prir@sumitomo-pharma.co.jp